Abstract: The invention relates to a liquid pharmaceutical concentrate comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 ?g, preferably at most 900 ng, more preferably at most 700 ng and ethanol. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the concentrate is diluted with a dilution liquid, preferably an aqueous dilution liquid, thereby obtaining a diluted composition, preferably a diluted solution. Said diluted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

Abstract: The invention relates to a reconstitutable solid pharmaceutical composition comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 ?g, preferably at most 900 ng, more preferably at most 500 ng; optionally, a surfactant; and optionally, a buffer. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the solid composition is reconstituted with a reconstitution liquid thereby obtaining a reconstituted composition. Said reconstituted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

Abstract: The invention relates to a pharmaceutical dosage form for injection, preferably intraarticular injection into a knee, comprising or essentially consisting of (i) Resiniferatoxin; preferably at a dose within the range of from 50 to 900 ng, preferably less than 500 ng; (ii) water; (iii) an organic solvent; preferably ethanol; (iv) a surfactant; preferably D-?-tocopherol polyethylene glycol succinate (TPGS); (v) optionally, a buffer; and (vi) optionally, one or more inorganic salts; wherein the weight content of the water is greater than the weight content of the organic solvent. The invention further relates to a liquid pharmaceutical dosage form comprising Resiniferatoxin at a dose within the range of from 50 to 900 ng, preferably less than 500 ng for use in the treatment of knee joint pain, preferably osteoarthritic knee joint pain, by intraarticular administration, preferably intraarticular injection.

Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Abstract: The invention relates to cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]-decan-2-one derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.

Abstract: Compounds according to general formula (I) act as inhibitors of NaV1.8 and can be used in the treatment of pain.

Abstract: The invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.

Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.

Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.

Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.

Abstract: The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.

Abstract: Spirocyclic cyclohexane compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and methods of using them.